Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Posts Earnings Results, Beats Expectations By $0.18 EPS

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) announced its quarterly earnings results on Monday. The company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.18, Zacks reports. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 13.56% and a net margin of 41.08%.

Shionogi & Co., Ltd. Unsponsored ADR Stock Performance

Shares of SGIOY stock opened at $9.04 on Monday. The company has a market capitalization of $15.39 billion, a P/E ratio of 11.30, a P/E/G ratio of 3.55 and a beta of 0.09. Shionogi & Co., Ltd. Unsponsored ADR has a 12-month low of $7.65 and a 12-month high of $12.00. The company has a quick ratio of 1.46, a current ratio of 1.58 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average price of $8.82 and a 200 day moving average price of $9.88.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on SGIOY. The Goldman Sachs Group raised Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Monday, June 15th. Zacks Research raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a report on Monday, May 25th. Finally, Jefferies Financial Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 14th. Two research analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to MarketBeat, Shionogi & Co., Ltd. Unsponsored ADR currently has an average rating of “Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.